Lasers Enable Automated Cell Line Instruments from CYTENA
In their words
“OBIS lasers give us three important advantages for our instruments – superior beam quality, unit-to-unit consistency, and long-term stability/reliability."
Dr. Lena Lautscham, Lead R&D Scientist, CYTENA, Freiburg, Germany, a CELLINK company
CYTENA, Freiburg, Germany, was started in 2014 with a mission to deliver automated and highly efficient instruments for improved cell line development. Based on the founders’ background in Micro-Systems Engineering they identified a broad need to benignly obtain a single live cell from a sample with 100% reliability and verifiability. Previously, used methods used were repetitive dilutions making extensive use of time-consuming manual pipetting. Target customers included pharma labs for example, who must be able to prove to regulatory bodies like the FDA that a line of cells originates from a single cloned mother cell.
Dr. Lena Lautscham, Lead R&D Scientist at CYTENA, explains, “CYTENA developed and patented core technology that’s somewhat similar to an inkjet printer. The company chose laser fluorescence imaging as the best technique to rapidly screen droplets for a single cell just before it is released from the instrument’s disposable cartridge nozzle. Most of these instruments use a 488nm OBIS laser from Coherent; we use other OBIS wavelengths to satisfy custom requests.” The image is captured on a CMOS camera, and image analysis software then determines key sorting criteria about the cell in real-time. If the droplet contains a single cell of the user-specified type, it is dropped into a collection tube or wellplate well. Any droplets with no cells, dead cells, other cell types, or multiple cells are vacuumed into a tube and discarded.
First generation instruments and software targeted simple cell sorting – dispensing by size and shape. The company then extended the technology to use fluorescent markers to assess cells for specific proteins, differentiate between life and dead cells, and would enables more than one cell type to be dispensed in a single run.
Dr. Lautscham states, “The OBIS lasers give us three important main advantages for our instruments. They have the superior beam quality we need to ensure our optics always provide uniform illumination of the target volume. They have the unit-to-unit consistency that is critical for our instrument quality and performance. And they provide long-term stability/reliability which virtually eliminates the need for field service due to any laser issues.”
The ongoing market success of their single-cell dispensers has been leveraged by CYTENA to diversify into other biotechnology automation products. The company was acquired by CELLINK in 2019, bringing a strong international sales and support network. The resultant growth is evidenced by a 500% increase in workspace and a 600% growth in personnel, and more importantly by the 200-plus laboratories worldwide that now rely on CYTENA instrumentation.